Northway et al. (1) described bronchopulmonary dysplasia (BPD) in 1967, in a group of large preterm infants, as severe lung injury resulting from mechanical ventilation and oxygen exposure. Subsequently, many aspects of the injury were reproduced by oxygen exposure of newborn mice (2). O'Brodovich and Mellins (3) reviewed BPD in 1985, emphasizing that the combination of oxidant injury and mechanical ventilation resulted in inflammation, fibrosis, and smooth muscle hypertrophy in the airways. With progress in neonatal care that includes antenatal glucocorticoids, surfactant treatments, and gentler ventilation strategies, large preterm infants seldom develop BPD. However, the disease today is the most common complication of care of infants born weighing <1 kg (4). Further, BPD occurs frequently in infants weighing <1 kg who do not have much lung disease soon after birth (5, 6). Therefore, the traditional tandem of oxygen and barotrauma is not the major factor initiating much of the lung injury in very preterm infants. If the infants are more immature and the causes of injury are not primarily mechanical ventilation and oxidant injury, the pathology likely will be different. Although multiple pathophysiologic mechanisms no doubt contribute to lung injury in the preterm, the new BPD may be primarily an aberration of lung development (Fig. 1).
Infants born at 24–28 wk gestation are just beginning to alveolarize the distal saccules of the lung in parallel with development of the alveolar capillary bed. Hislop et al. (7) reported that ventilation of low birth weight infants yielded lungs with fewer alveoli. Husain et al. (8) recently reported that infants dying of BPD in the recent era of surfactant treatment had fewer and larger alveoli with less striking fibrosis and inflammation than in the past. Stahlman has found remarkable histopathology in infants dying of BPD after several months of ventilation. The lungs have minimal inflammation or fibrosis, but the saccular lung seems to have an arrest in alveolar and vascular development corresponding to the gestation of the infant at delivery (M.T. Stahlman, personal communication). These observations suggest, at least in infants dying of BPD, that the major manifestation of lung injury is an interference with normal lung development.
This arrest of lung development can be reproduced in preterm animals. Coalson et al. (9) found that exposure of baboons delivered at 140 d gestation (term is 186 d) to 100% oxygen and ventilation for 7 d decreased alveolar number by approximately 50% when the animals were 33 wk old relative to preterm baboons ventilated with less oxygen. This study emphasized the old association of oxygen with BPD. However, a similar pathology also occurred if baboons were delivered at 125 d gestation, surfactant-treated, and ventilated with <50% oxygen. Albertine et al. (10) ventilated 125-d-gestation surfactant-treated preterm lambs (term is 150 d) for 3 wk by using routine ventilation strategies and minimal supplemental oxygen. They found a complete arrest of alveolar septation that resulted in fewer and larger alveoli. Vascular development also was arrested. The animal models and clinical correlates show that the new BPD is characterized by an arrest of lung development and that the traditional indicators of injury are less evident.
WHAT REGULATES ALVEOLARIZATION?
The normal signals for alveolar septation are not known. However, in experimental animals, alveolar development can be delayed with hypoxia or hyperoxia, glucocorticoids, or poor nutrition (11). Transgenic mice provide some clues about factors that can disrupt lung development. Overexpression of TNF-α in the pulmonary epithelium during development results in decreased alveolar number and inflammation (12). Overexpression of TGF-α results in fewer and larger alveoli and fibrosis (13). Overexpression of IL-11 in the airways of newborn mice also results in fewer and larger alveoli, and overexpression of IL-6 causes lymphocytic infiltrate in the lungs and fewer and larger alveoli (14, 15). The common thread is that cytokine overexpression can interfere with the normal postnatal alveolarization in mice. The glucocorticoid-induced inhibition of alveolarization can be blocked in newborn rats with retinoic acid (16). These observations tell us what can interfere with alveolarization but do not provide insights into the normal signals for alveolar development.
LUNG MATURATION
The human fetal lung normally is not mature clinically until after approximately 35 wk gestation. In contrast, 26-wk-gestation infants with essentially no lung disease are frequent, demonstrating induced lung maturation. An axiom of neonatology is that fetal stress matures the preterm lung. However, recent clinical reports indicate that the incidence of respiratory distress syndrome (RDS) is not reduced in growth-retarded infants (17), infants from preeclamptic pregnancies (18), or after prolonged preterm rupture of membranes (19). How can growth-retarded infants not be stressed sufficiently to induce lung maturation, whereas normally grown infants born at 26 wk can have mature lungs? Antenatal glucocorticoids decrease the incidence of RDS, but they seem to decrease the incidence by only 40 to 50% (20). Repetitive courses of treatment may not further decrease the incidence of RDS (21). Why are glucocorticoids not more effective even when given repetitively? We recently reported that maternal betamethasone treatments resulted in both fetal growth retardation and lung maturation, whereas fetal betamethasone treatments resulted in less lung maturation and no fetal growth retardation in sheep (22). The particularly curious aspect to the observation was that plasma betamethasone levels were 3-fold higher after fetal than maternal treatments (23).
In transgenic mice, very low fetal plasma glucocorticoid levels resulting from corticotropin-releasing hormone deficiency (CRH-/-) delayed anatomic maturation of the distal lung parenchyma with minimal effects on the surfactant system (24). However if the CRH-/- fetuses develop in CRH+/- dams or if CRH-/- dams received supplemental glucocorticoids, lung maturation proceeded normally. A very low fetal glucocorticoid level resulting from some placental transfer from dam to fetus was sufficient to sustain normal maturation. The effects of glucocorticoids on the preterm lung are confusing and complex because glucocorticoids can interfere with alveolarization while at the same time they induce structural maturation by thinning the mesenchyme and induce the surfactant system (11, 22, 25, 26). The effects depend on timing during development, dose, and certainly other factors. Interactions between glucocorticoids and cytokines are likely but have not been studied in relation to lung maturation. The bottom line is that we do not know what factors regulate normal lung maturation or what factors might optimally induce early lung maturation. Glucocorticoids are helpful, but they are only part of the story.
CYTOKINES AND LUNG MATURATION
Chronic low-grade infection/inflammation of fetal membranes and amniotic fluid is common for pregnancies that deliver very preterm (27). Histologic chorioamnionitis is associated with a decrease in RDS but an increase in BPD in one series (28). Elevated levels of the proinflammatory cytokines TNF-α, IL-1β, IL-6, and IL-8 in amniotic fluid are associated with an increased risk of BPD (29, 30). Ureaplasma urealyticum, the most common contaminant of amniotic fluid, elicits an inflammatory response in amniotic fluid and has been associated with BPD (31). These clinical observations are consistent with the interference with lung development by a proinflammatory cytokine that occurs in transgenic mice (12–15). However, cytokine effects on the developing lung need not be all bad. The proinflammatory cytokine IL-1α increased mRNA for the surfactant proteins SP-A and SP-B and improved the compliances of ventilated preterm rabbits (32). We recently found that intraamniotic endotoxin was a more potent inducer of lung maturation and the surfactant system than was betamethasone in preterm sheep (33). These observations suggest the counterintuitive hypothesis that proinflammatory cytokines can act as maturational signals in the fetus. Cytokines may have signaling roles during normal lung development as well as during lung injury and repair.
VENTILATION AND LUNG INJURY
Normal ventilation and ambient oxygen exposure may act as promoters and propagators of injury in the preterm lung. In the adult animal, ventilation with gas volumes that approach or exceed total lung capacity results in pulmonary edema and proinflammatory cytokine release in the lungs (34). Ventilation from volumes below a normal functional residual capacity also results in edema, inflammation, and proinflammatory cytokine release. Prior exposure of the isolated and perfused lung to endotoxin amplifies the ventilation-mediated injury (35). Lung gas volumes are low in preterm infants, functional residual capacities are low and unstable, and inflation is nonuniform because of surfactant deficiency (36). Modest hyperventilation of preterm lambs to PCO2 values of 25–30 mm Hg is sufficient to induce TNF-α mRNA within 2 h (M. Ikegami, unpublished data). What if the lung has been primed by exposure to antenatal proinflammatory cytokines? Routine resuscitation and the subsequent ventilation and oxygen exposure of very preterm infants may amplify lung injury after antenatal cytokine exposure.
The important concept is that the lung is just beginning to develop into a gas exchange organ over the 24–28-wk gestation interval (7, 37). Very preterm birth may result in the release of signaling molecules that can interfere with lung development. Antenatal or early postnatal inflammation may compound the adverse effects on lung development. We know very little about how the preterm fetus mounts an inflammatory response or how the fetal lung responds to inflammatory mediators. The enticing prospect is that some of the mediators are beneficial (e.g. lung maturation induced by IL-1α) and others are almost certainly detrimental (e.g. the correlations of elevated TNF-α and IL-6 with BPD) (29, 32). Deconvoluting the fetal inflammatory response and the postnatal effects of proinflammatory mediators on the lungs should yield new strategies to improve outcomes for preterm infants. Another major benefit will be new knowledge about the process of alveolarization of the lung—insights into the pathophysiology of the new BPD.
References
Northway WH Jr, Rosan RC, Porter DY 1967 Pulmonary disease following respirator therapy of hyaline-membrane disease. N Engl J Med 276: 357–368
Bonikos DS, Bensch KG, Ludwin SK, Northway WH 1975 Oxygen toxicity in the newborn. Lab Invest 32: 619–635
O'Brodovich HM, Mellins RB 1985 Bronchopulmonary dysplasia. Am Rev Respir Dis 132: 694–709
Stevenson DK, Wright LL, Lemons JA, Oh W, Korones SB, Papile L, Bauer CR, Stoll BJ, Tyson JE, Shankaran S, Fanaroff AA, Donovan EF, Ehrenkranz RA, Verter J 1998 Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol 179: 1632–1639
Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G 1995 Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 126: 605–610
Charafeddine L, D'Angio CT, Phelps DL 1999 Atypical chronic lung disease patterns in neonates. Pediatrics 103: 759–765
Hislop AA, Wigglesworth JS, Desai R 1986 Alveolar development in the human fetus and infant. Early Hum Dev 13: 1–11
Husain NA, Siddiqui NH, Stocker JR 1998 Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 29: 710–717
Coalson JJ, Winter V, deLemos RA 1995 Decreased alveolarization in baboon survivors with bronchopulmonary dysplasia. Am J Respir Crit Care Med 152: 640–646
Albertine KH, Jones GP, Starcher BC, Bohnsack JF, Davis PL, Cho S, Carlton DP, Bland RD 1999 Chronic lung injury in preterm lambs. Am J Respir Crit Care Med 159: 945–958
Massaro GD, Massaro D 1996 Formation of pulmonary alveoli and gas-exchange surface area: quantitation and regulation. Annu Rev Physiol 58: 73–92
Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, Piguet PF, Vassalli P 1995 Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. J Clin Invest 96: 250–259
Hardie WD, Bruno MD, Huelsman KM, Iwamoto HS, Carrigan PE, Leikauf GD, Whitsett JA, Korfhagen TR 1997 Postnatal lung function and morphology in transgenic mice expressing transforming growth factor-alpha. Am J Path 151: 1075–1083
Ray P, Tang W, Wang P, Homer R, Kuhn C, Flavell RA, Elias JA 1997 Regulated overexpression of interleukin-11 in the lung. J Clin Invest 100: 2501–2511
DiCosmo BF, Geba GP, Picarella D, Elias JA, Rankin JA, Stripp BR, Whitsett JA, Flavell RA 1994 Airway epithelial cell expression of interleukin-6 in transgenic mice. J Clin Invest 94: 2028–2035
Massaro GD, Massaro D 1996 Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 270: L305–L310
Tyson JE, Kennedy K, Broyles S, Rosenfeld CR 1995 The small for gestational age infant: accelerated or delayed pulmonary maturation? Increased or decreased survival?. Pediatrics 95: 534–538
Friedman SA, Schiff E, Kao L, Sibai BM 1995 Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 172: 1785–1792
Hallak M, Bottoms SF 1993 Accelerated pulmonary maturation from preterm premature rupture of membranes: a myth. Am J Obstet Gynecol 169: 1045–1049
Crowley P 1995 Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 173: 322–335
French NP, Hagan R, Evans SF, Godfrey M, Newnham JP 1999 Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 180: 114–121
Jobe AH, Newnham J, Willet K, Sly P, Ikegami M 1998 Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics 102: 1116–1125
Berry LM, Polk DH, Ikegami M, Jobe AH, Padbury JF, Ervin MG 1997 Preterm newborn lamb renal and cardiovascular responses after fetal or maternal antenatal betamethasone. Am J Physiol 272: R1972–R1979
Muglia LJ, Bae DS, Brown TT, Vogt SK, Alvarez JG, Sunday ME, Majzoub JA 1999 Proliferation and differentiation defects during lung development in corticotropin-releasing hormone-deficient mice. Am J Respir Cell Mol Biol 20: 181–188
Bunton TE, Plopper CG 1984 Triamcinolone-induced structural alterations in the development of the lung of the fetal rhesus macaque. Am J Obstet Gynecol 148: 203–215
Pinkerton KE, Willet KE, Peake J, Sly PD, Jobe AH, Ikegami M 1997 Prenatal glucocorticoid and T4 effects on lung morphology in preterm lambs. Am J Respir Crit Care Med 156: 624–630
Watts DH, Krohn KA, Hillier SL, Eschenbach DA 1992 The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet Gynecol 79: 351–357
Watterberg KL, Demers LM, Scott SM, Murphy S 1996 Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97: 210–215
Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI 1997 Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 177: 825–830
Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM 1998 The fetal inflammatory response syndrome. Am J Obstet Gynecol 179: 194–202
Yoon BH, Romero R, Park JS, Chang JW, Kim YA, Kim JC, Kim KS 1998 Microbial invasion of the amniotic cavity with ureaplasma urealyticum is associated with a robust host in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol 179: 1254–1260
Bry K, Lappalainen U, Hallman M 1997 Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J Clin Invest 99: 2992–2999
Jobe AH, Newnham JP, Willet KE, Sly P, Ervin MG, Bachurski C, Possmayer F, Hallman M, Ikegami M 1999 Antenatal endotoxin and glucocorticoid effects on the lungs of preterm lambs. Am J Obstet Gynecol: In press
Dreyfuss D, Saumon G 1998 Ventilator-induced lung injury. Am J Respir Crit Care Med 157: 294–323
Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS 1997 Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 99: 944–952
Jobe AH, Ikegami M 1998 Mechanisms initiating lung injury in the preterm. Early Hum Dev 53: 81–94
Langston C, Kida D, Reed M, Thurlbeck W 1984 Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 129: 607–613
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jobe, A. The New BPD: An Arrest of Lung Development. Pediatr Res 46, 641 (1999). https://doi.org/10.1203/00006450-199912000-00007
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199912000-00007
This article is cited by
-
Glucocorticosteroids and bronchopulmonary dysplasia : is epigenetics the missing link?
Pediatric Research (2024)
-
Leveraging transcriptomics to develop bronchopulmonary dysplasia endotypes: a concept paper
Respiratory Research (2023)
-
Loss of microRNA-30a and sex-specific effects on the neonatal hyperoxic lung injury
Biology of Sex Differences (2023)
-
The artificial placenta and EXTEND technologies: one of these things is not like the other
Journal of Perinatology (2023)
-
Metabolome and microbiome multi-omics integration from a murine lung inflammation model of bronchopulmonary dysplasia
Pediatric Research (2022)